Syneron Medical (ELOS) Posts Q2 non-GAAP Loss of $0.12, In-Line with Views
Syneron Medical Ltd. (Nasdaq: ELOS) reports Q2 non-GAAP loss of $0.12, even with the analyst estimate of ($0.12). Revenue for the quarter was $48.6 million, which compares to the estimate of $46.60 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelength
- Cadence Design Systems (CDNS) Tops Q2 EPS by 1c; Guides Below the Street
- Gilead Sciences (GILD) Tops Q2 EPS by 6c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!